ZURICH, Sept 12 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Tuesday:
NOVARTIS NOVN.S
Novartis AG said its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).
For more, click on NOVN.S
COMPANY STATEMENTS CPR-CH
* Basilea BSLN.S said it entered into a distribution agreement with Cardiome Pharma Corp COM.TO for Basilea's antibiotic Zevtera/Mabelio (ceftobiprole) in Europe, excluding Nordic countries, and Israel. BSLN.S
* CNP, a consortium consisting of Alpiq ALPH.S , Axpo and BKW BKWB.S , said it is terminating a contract with EDF EDF.PA for the procurement of electricity from the Fessenheim nuclear power plant. ALPH.S BKWB.S
* Dormakaba DOKA.S said net profit increased to 224.6 million Swiss francs in 2016/2017 due to higher profitability and positive tax effects of acquisitions and post-merger integration. DOKA.S
* Partners Group PGHN.S said IFRS profit increased by 42 percent year on year to 359 million Swiss francs in the first half. PGHN.S
* Romande Energie HREN.S said net profit fell to 34 million Swiss francs in the first half. HREN.S
ECONOMY M-CH
Swiss federal bond SWIW announcement due at 0600 GMT